AEPAD – Auditory Evoked Potentials as potential biomarkers for AD
Research type
Research Study
Full title
Testing the feasibility of recording multiple auditory-evoked potentials to identify novel biomarkers for Alzheimer’s Disease
IRAS ID
334314
Contact name
Navid Banafshe
Contact email
Sponsor organisation
Neso Technology Ltd.
Duration of Study in the UK
0 years, 6 months, 28 days
Research summary
With the ageing population, neurodegenerative diseases such as Alzheimer’s disease are on the rise. While the population above 65 years is expected to double by 2050, the number of patients affected by dementia will triple. Most treatments for Alzheimer’s Disease work better when given early in the disease course. An early, accurate, affordable and accessible diagnosis of Alzheimer’s Disease is therefore critical to improve clinical outcomes and patient’s quality of life.
This study aims to test the feasibility of a combination of new auditory stimulation sequences and analytical techniques for the diagnosis of Alzheimer's Disease. Hearing impairment can increase the risk of dementia and past research has shown that patients affected by Alzheimer’s Disease have difficulties in processing certain auditory stimuli. We plan to test a battery of different auditory stimuli in a feasibility study involving 15 Alzheimer’s patients and 15 healthy controls in a collaboration between the University of Surrey, Surrey and Borders NHS Foundation Trust and the sponsor of the study Neso Technology Ltd.REC name
West Midlands - Coventry & Warwickshire Research Ethics Committee
REC reference
25/WM/0030
Date of REC Opinion
10 Apr 2025
REC opinion
Further Information Favourable Opinion